Sinovac Biotech Ltd.  

(Public, NASDAQ:SVA)   Watch this stock  
6.10
-0.05 (-0.81%)
Real-time:   1:14PM EST
NASDAQ real-time data - Disclaimer
Currency in USD
Range 6.08 - 6.15
52 week 4.38 - 7.16
Open 6.15
Vol / Avg. 13,483.00/53,976.00
Mkt cap 349.98M
P/E     -
Div/yield     -
EPS -0.19
Shares 56.91M
Beta 0.29
Inst. own 40%
Nov 28, 2016
Q3 2016 Sinovac Biotech Ltd Earnings Release
Nov 28, 2016
Q3 2016 Sinovac Biotech Ltd Earnings Call
Nov 6, 2016
Sinovac Biotech Ltd Annual Shareholders Meeting
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '16) 2015
Net profit margin -912.35% 0.76%
Operating margin -1001.38% 5.52%
EBITD margin - 14.83%
Return on average assets -26.11% 0.23%
Return on average equity -32.60% -0.28%
Employees 646 -
CDP Score - -

Address

39 Shangdi Xi Road, Haidian District
BEIJING, BEJ 100085
China
+86-10-82890088 (Phone)
+86-10-62966910 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Sinovac Biotech Ltd. (Sinovac) is a holding company. The Company is a biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases, including hepatitis A, hepatitis B, seasonal influenza, Haemagglutinase5 Neuraminidase1 (H5N1) and Influenza A (H1N1) pandemic influenza and mumps. The Company's pipeline consists of vaccine candidates in the clinical and pre-clinical development Phases in China. The Company is engaged in the sales, marketing, manufacturing and development of vaccines for infectious disease. The Company develops various products, including Healive, Bilive, Anflu, Panflu Whole Viron Pandemic Influenza Vaccine, Split Viron Pandemic Influenza Vaccine, Panflu.1, RabEnd, Mumps Vaccine, Enterovirus 71 (EV71) Vaccine, Pneumococcal Polysaccharide Vaccine, Pneumococcal Conjugate Vaccine, Rubella Vaccine, Varicella Vaccine and Sabin Inactivated Polio Vaccine.

Officers and directors

Weidong Yin Chairman of the Board, President, Chief Executive Officer, Secretary
Age: 48
Bio & Compensation  - Reuters
Nan Wang Chief Financial Officer
Age: 46
Bio & Compensation  - Reuters
Ming Xia Vice President - Sales and Marketing of Sinovac Beijing
Age: 38
Bio & Compensation  - Reuters
Simon J. Anderson Independent Director
Age: 53
Bio & Compensation  - Reuters
Jue Lee Independent Director
Age: 47
Bio & Compensation  - Reuters
Yuk Lam Lo Independent Director
Age: 67
Bio & Compensation  - Reuters
Meng Mei Independent Director
Age: 58
Bio & Compensation  - Reuters